Long term follow-up of Behcet's syndrome patients treated with cyclophosphamide

Gurcan, Mert; Esatoglu, Sinem; HAMURYUDAN, Vedat; Saygin, Didem; UĞURLU, Serdal; SEYAHİ, Emire; MELİKOĞLU, Melike; FRESKO, İzzet; Yurdakul, Sebahattin; Yazici, Hasan; HATEMİ, Gülen

doi:10.1093/rheumatology/kez598

Long term follow-up of Behcet's syndrome patients treated with cyclophosphamide

Gurcan M., Esatoglu S. N., HAMURYUDAN V., Saygin D., UĞURLU S., SEYAHİ E., ...More

RHEUMATOLOGY, vol.59, no.9, pp.2264-2271, 2020 (SCI-Expanded)

Publication Type: Article / Article
Volume: 59 Issue: 9
Publication Date: 2020
Doi Number: 10.1093/rheumatology/kez598
Journal Name: RHEUMATOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
Page Numbers: pp.2264-2271
Istanbul University Affiliated: Yes

Abstract

Objectives. CYC remains an important treatment option for Behcet's syndrome (BS) patients with life-threatening manifestations. However, adverse events may occur with CYC and this has led to increased use of biologic agents in other vasculitides. We investigated short and long term adverse events associated with CYC use in BS patients.